CCI study: Anti-platelet, anticoagulant treatment warranted in PCI patients with AF

06/30/2013 | Healio

A combination of anti-platelet and anticoagulant therapy is appropriate for atrial fibrillation patients who are undergoing PCI to mitigate stroke risk, according to a prospective, multicenter study reported in Catheterization and Cardiovascular Interventions. The study also found that vitamin K antagonist therapy should not be discontinued prior to PCI.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC